Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR-T Therapy

06:01 EDT 18 Aug 2017 | Genetic Engineering News

Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN ® gene-edited chimeric antigen receptor (CAR) T-cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from the start in June of a Phase I study to evaluate the safety and efficacy of UCART123 in patients with acute myeloid leukemia (AML). Cellectis  says UCART123 is the first allogeneic, off-the-shelf, gene-edited CAR T-cell program targeting CD123 to enter clinical trials in the U.S. BPDCN is a rare, aggressive hematological cancer classified as an acute leukemia, for which there is no standardized therapeutic approach. Most BPDCN patients may achieve transient responses when treated using combination chemotherapy regimens for acute leukemia or lymphoma, but then they relapse. The new Phase I UCART123 study, carried out the MD Anderson Cancer Center, will evaluate the cell therapy in ...

Original Article: Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR-T Therapy


More From BioPortfolio on "Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR-T Therapy"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...